TipRanks
Roivant Sciences (DE:87S)
FRANKFURT:87S
Germany Market
87S
Roivant Sciences
RESEARCH TOOLSreports

Roivant Sciences (87S) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

87S Analyst Ratings

Strong Buy
12Ratings
Strong Buy
10 Buy
2 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Roivant
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

87S Stock 12 Month Forecast

Average Price Target

€42.56
▲(47.11% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is €42.56 with a high forecast of €55.20 and a low forecast of €35.61. The average price target represents a 47.11% change from the last price of €28.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","56":"€56","22.25":"€22.3","33.5":"€33.5","44.75":"€44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55.2016907,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€55.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.558722829999994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€42.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.613994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,22.25,33.5,44.75,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,33.572437746153845,35.374875492307694,37.17731323846154,38.979750984615386,40.78218873076923,42.58462647692308,44.38706422307692,46.18950196923077,47.99193971538462,49.79437746153846,51.5968152076923,53.39925295384616,{"y":55.2016907,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,32.59990175615385,33.42980351230769,34.25970526846154,35.08960702461538,35.91950878076923,36.74941053692307,37.57931229307692,38.40921404923076,39.239115805384614,40.06901756153846,40.898919317692304,41.72882107384615,{"y":42.558722829999994,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,32.06569184615385,32.36138369230769,32.65707553846154,32.952767384615385,33.24845923076923,33.54415107692308,33.83984292307692,34.135534769230766,34.43122661538462,34.72691846153846,35.022610307692304,35.318302153846155,{"y":35.613994,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.455,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.165,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.02,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.79,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.03,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.77,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€55.20Average Price Target€42.56Lowest Price Target€35.61
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on DE:87S
Yaron Werber
TD Cowen
TD Cowen
€48.97→€55.2
Buy
90.81%
Upside
Reiterated
10/21/26
Roivant Sciences price target raised to $62 from $55 at TD CowenRoivant Sciences price target raised to $62 from $55 at TD Cowen
H.C. Wainwright Analyst forecast on DE:87S
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
€41.85
Buy
44.65%
Upside
Reiterated
10/21/26
Analysts Conflicted on These Healthcare Names: Roivant Sciences (NASDAQ: ROIV), Alnylam Pharma (NASDAQ: ALNY) and Haemonetics (NYSE: HAE)
Bank of America Securities Analyst forecast on DE:87S
Chi Meng Fong
Bank of America Securities
Bank of America Securities
€36.5
Hold
26.18%
Upside
Reiterated
10/21/26
Analysts Conflicted on These Healthcare Names: Roivant Sciences (NASDAQ: ROIV) and 4D Molecular Therapeutics (NASDAQ: FDMT)
Wolfe Research Analyst forecast on DE:87S
Andy Chen
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
10/12/26
Roivant Sciences downgraded to Peer Perform from Outperform at Wolfe ResearchRoivant Sciences downgraded to Peer Perform from Outperform at Wolfe Research
Citi Analyst forecast on DE:87S
Samantha Semenkow
Citi
Citi
€40.96
Buy
41.57%
Upside
Assigned
10/12/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Bristol-Myers Squibb (NYSE: BMY) and Palvella Therapeutics (NASDAQ: PVLA)
Bernstein Analyst forecast on DE:87S
Eve Burstein
Bernstein
Bernstein
€36.5
Buy
26.18%
Upside
Reiterated
09/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (NASDAQ: ROIV) and Johnson & Johnson (NYSE: JNJ)
Stifel Nicolaus Analyst forecast on DE:87S
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€45.41
Buy
56.96%
Upside
Initiated
09/17/26
Roivant Sciences initiated with a Buy at StifelRoivant Sciences initiated with a Buy at Stifel
J.P. Morgan Analyst forecast on DE:87S
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/17/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on DE:87S
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€37.39→€46.3
Buy
60.04%
Upside
Reiterated
09/16/26
Leerink Partners Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Guggenheim Analyst forecast on DE:87S
Yatin Suneja
Guggenheim
Guggenheim
€37.39→€40.96
Buy
41.57%
Upside
Reiterated
09/08/26
Analysts' Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)
Jefferies Analyst forecast on DE:87S
Dennis Ding
Jefferies
Jefferies
€37.39→€46.3
Buy
60.04%
Upside
Reiterated
09/08/26
Roivant Sciences price target raised to $52 from $42 at JefferiesRoivant Sciences price target raised to $52 from $42 at Jefferies
Piper Sandler Analyst forecast on DE:87S
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€35.61
Buy
23.10%
Upside
Reiterated
08/28/26
Piper Sandler Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Goldman Sachs Analyst forecast on DE:87S
Corinne Johnson
Goldman Sachs
Goldman Sachs
€33.83→€36.5
Buy
26.18%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Ovid Therapeutics (NASDAQ: OVID) and Legend Biotech (NASDAQ: LEGN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on DE:87S
Yaron Werber
TD Cowen
TD Cowen
€48.97→€55.2
Buy
90.81%
Upside
Reiterated
10/21/26
Roivant Sciences price target raised to $62 from $55 at TD CowenRoivant Sciences price target raised to $62 from $55 at TD Cowen
H.C. Wainwright Analyst forecast on DE:87S
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
€41.85
Buy
44.65%
Upside
Reiterated
10/21/26
Analysts Conflicted on These Healthcare Names: Roivant Sciences (NASDAQ: ROIV), Alnylam Pharma (NASDAQ: ALNY) and Haemonetics (NYSE: HAE)
Bank of America Securities Analyst forecast on DE:87S
Chi Meng Fong
Bank of America Securities
Bank of America Securities
€36.5
Hold
26.18%
Upside
Reiterated
10/21/26
Analysts Conflicted on These Healthcare Names: Roivant Sciences (NASDAQ: ROIV) and 4D Molecular Therapeutics (NASDAQ: FDMT)
Wolfe Research Analyst forecast on DE:87S
Andy Chen
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
10/12/26
Roivant Sciences downgraded to Peer Perform from Outperform at Wolfe ResearchRoivant Sciences downgraded to Peer Perform from Outperform at Wolfe Research
Citi Analyst forecast on DE:87S
Samantha Semenkow
Citi
Citi
€40.96
Buy
41.57%
Upside
Assigned
10/12/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Bristol-Myers Squibb (NYSE: BMY) and Palvella Therapeutics (NASDAQ: PVLA)
Bernstein Analyst forecast on DE:87S
Eve Burstein
Bernstein
Bernstein
€36.5
Buy
26.18%
Upside
Reiterated
09/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (NASDAQ: ROIV) and Johnson & Johnson (NYSE: JNJ)
Stifel Nicolaus Analyst forecast on DE:87S
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
€45.41
Buy
56.96%
Upside
Initiated
09/17/26
Roivant Sciences initiated with a Buy at StifelRoivant Sciences initiated with a Buy at Stifel
J.P. Morgan Analyst forecast on DE:87S
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/17/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on DE:87S
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€37.39→€46.3
Buy
60.04%
Upside
Reiterated
09/16/26
Leerink Partners Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Guggenheim Analyst forecast on DE:87S
Yatin Suneja
Guggenheim
Guggenheim
€37.39→€40.96
Buy
41.57%
Upside
Reiterated
09/08/26
Analysts' Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)
Jefferies Analyst forecast on DE:87S
Dennis Ding
Jefferies
Jefferies
€37.39→€46.3
Buy
60.04%
Upside
Reiterated
09/08/26
Roivant Sciences price target raised to $52 from $42 at JefferiesRoivant Sciences price target raised to $52 from $42 at Jefferies
Piper Sandler Analyst forecast on DE:87S
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€35.61
Buy
23.10%
Upside
Reiterated
08/28/26
Piper Sandler Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Goldman Sachs Analyst forecast on DE:87S
Corinne Johnson
Goldman Sachs
Goldman Sachs
€33.83→€36.5
Buy
26.18%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Ovid Therapeutics (NASDAQ: OVID) and Legend Biotech (NASDAQ: LEGN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
SIBNSI-Bone
IMUXImmunic
MDWDMediwound
HROWHarrow Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roivant Sciences

3 Months
Brian ChengJ.P. Morgan
Success Rate
18/22 ratings generated profit
82%
Average Return
+19.36%
Copying Brian Cheng's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +19.36% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
32/35 ratings generated profit
91%
Average Return
+75.31%
Copying David Risinger's trades and holding each position for 1 Year would result in 91.43% of your transactions generating a profit, with an average return of +75.31% per trade.
2 Years
David RisingerLeerink Partners
Success Rate
34/35 ratings generated profit
97%
Average Return
+143.02%
Copying David Risinger's trades and holding each position for 2 Years would result in 97.14% of your transactions generating a profit, with an average return of +143.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

87S Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
1
Buy
11
8
12
20
21
Hold
2
3
3
4
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
11
15
24
28
In the current month, 87S has received 22 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 87S average Analyst price target in the past 3 months is 42.56.
Each month's total comprises the sum of three months' worth of ratings.

87S Financial Forecast

87S Earnings Forecast

Next quarter’s earnings estimate for 87S is -€0.33 with a range of -€0.53 to -€0.17. The previous quarter’s EPS was -€0.30. 87S beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 87S has Performed in-line its overall industry.
Next quarter’s earnings estimate for 87S is -€0.33 with a range of -€0.53 to -€0.17. The previous quarter’s EPS was -€0.30. 87S beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 87S has Performed in-line its overall industry.

87S Sales Forecast

Next quarter’s sales forecast for 87S is €3.33M with a range of €0.00 to €7.14M. The previous quarter’s sales results were €1.29M. 87S beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 87S has Performed in-line its overall industry.
Next quarter’s sales forecast for 87S is €3.33M with a range of €0.00 to €7.14M. The previous quarter’s sales results were €1.29M. 87S beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 87S has Performed in-line its overall industry.

87S Stock Forecast FAQ

What is DE:87S’s average 12-month price target, according to analysts?
Based on analyst ratings, Roivant Sciences’s 12-month average price target is 42.56.
    What is DE:87S’s upside potential, based on the analysts’ average price target?
    Roivant Sciences has 47.11% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Roivant Sciences a Buy, Sell or Hold?
          Roivant Sciences has a consensus rating of Strong Buy, which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Roivant Sciences’s share price target?
            The average share price target for Roivant Sciences is 42.56. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €55.20 ,and the lowest forecast is €35.61. The average share price target represents 47.11% Increase from the current price of €28.93.
              What do analysts say about Roivant Sciences?
              Roivant Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Roivant Sciences?
                To buy shares of DE:87S, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.